Bristol-Myers' Opdivo-Yervoy combo scores again at FDA, this time in colorectal cancer
admin 27th March 2018 Uncategorised 0Last August, Bristol-Myers Squibb’s Opdivo nabbed an approval to treat specific types of colorectal cancer. And Tuesday, it took a step toward nabbing that indication again—but this time alongside fellow BMS immunotherapy Yervoy.
More: Bristol-Myers' Opdivo-Yervoy combo scores again at FDA, this time in colorectal cancer
Source: fierce